Glucotrack Announces Innovate GBM’s First Partnership with Two Teams to Assess Brain Tumor Therapies
Key Facts
Glucotrack announced on September 23, 2026, that Innovate GBM had engaged two teams from the ai² PIPELINE project to identify and assess therapeutic assets for brain tumors for licensing and development. The company said Innovate GBM was the first external organization to receive Lōkahi Therapeutics’ practical therapeutic-asset identification services. This corrects any description of the step as a first new external partnership; the announcement places its precedence in September and does not establish a new agreement on October 28. The company described the collaboration as fee-for-service, but did not disclose the fee or specify expected revenue from it. The agreement puts the asset-assessment model before an external organization for the first time, without by itself establishing the scale of its financial contribution.
According to Glucotrack’s statement, Innovate GBM’s teams will focus on therapeutic assets for glioblastoma and other brain tumors. The company said Innovate GBM would independently decide whether to pursue any identified asset, leaving the decision to move from assessment to development with the collaborating organization. This means the announcement covers research and assessment in preparation for potential licensing and development, not the announcement of a treatment already selected or a completed licensing deal. This external use comes within a process that Lōkahi said it had been carrying out through a network of 14 university collaborations. The company had described that network as the infrastructure supporting its asset-identification and assessment process.
On October 1, Glucotrack announced a project bringing together the University of Georgia and Germany’s Paderborn University, presenting it as the first international expansion of Lōkahi’s university-based asset-assessment model. The initiative is scheduled to take place in fall 2026, with multidisciplinary student teams from the United States and Germany. According to the company’s description, the teams will assess pharmaceutical and biotechnology assets developed, marketed or deprioritized outside the United States. The work aims to explore the possibility of licensing these assets in the United States, acquiring them or subjecting them to further strategic assessment. The company’s fall announcements therefore include two tracks for the model: an assessment service for an external organization and an international university project.
Lōkahi’s business development comes alongside its public launch of the Qare platform on October 14, 2026. The platform began with GLP-1 drugs and allows users to compare self-reported outcomes, side effects and out-of-pocket costs with users who have similar profiles. Lōkahi said it expects to add other therapeutic categories through organic growth and industry partnerships. It also said growth in its user base could support future research and industry partnerships. This track adds a user-facing business alongside therapeutic-asset identification and university collaboration.
As for the stock, GCTK closed at $1.7100 in the October 27 session, up 6.21%, according to Investing.com data. The stock recorded a high of $1.7600 and a low of $1.2901 in the same session, with 4.72 million shares traded. This data precedes the story circulating on October 28, so it does not establish that the move came in response to a partnership announcement that day. The company’s stock had undergone a 1-for-2 reverse split that took effect at the opening of trading on October 26. Glucotrack said the split was intended, in part, to help regain compliance with Nasdaq’s minimum bid-price requirement of $1.00 per share.
Under the terms of the exception announced by the company, it must maintain a closing bid price of at least $1.00 on every trading day through November 9, 2026. That places the stock’s post-split movement within a defined compliance period, alongside the company’s efforts to develop Lōkahi’s activities. The outcomes of the Innovate GBM collaboration remain tied to asset assessment and the collaborating organization’s independent decision on whether to pursue any of them. The two-university project is set for the fall, while Lōkahi said adding therapeutic areas to Qare could take place through organic growth or partnerships. The November 9 deadline is the next specified date Glucotrack has announced regarding Nasdaq requirements.